Skip to main content

When opportunity meets ability: The moderating effects of prolific inventors on novel drug innovation following product development failure in biotechnology [Hybrid]

Pictured: Amrita Lahiri

Amrita Lahiri

In case of adverse events such as product development failure, managers often rely on the firm’s prolific inventors to help the firm recover and create novel products. Our study shows that there are limits to this approach. We show that in times of adversity, firms with prolific inventors are less likely to create new novel knowledge than firms with no prolific inventors. We further establish that the presence of prolific inventors with greater collaborative strength and long tenures are especially likely to reduce firms’ pursuit of novel products, while the presence of those with low collaborative strength and tenure tend to increase this propensity.